GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL) has announced the publication of a peer-reviewed article in the European Journal of Internal Medicine, which presents positive clinical results and a strong safety profile for its investigational drug AD04. The drug, designed to treat Alcohol Use Disorder (AUD), showed no significant changes in liver biochemical markers or adverse effects among patients.
The study focused on AD04's liver safety compared to a placebo in subjects with AUD, particularly those with a specific genetic profile. This genetic profile is linked to compulsive alcohol consumption and a higher risk of alcohol-associated liver disease (ALD), a leading cause of liver transplants and mortality worldwide.
In the trials, AD04 did not significantly impact liver injury markers such as ALT, AST, and Serum Bilirubin, and maintained stable GGT levels, which are often elevated due to excessive alcohol consumption. The publication underscored the drug's exceptional safety and tolerability, noting its low adverse event occurrence, high medication compliance, and minimal dropout rate.
Cary Claiborne, CEO of Adial, stated that the current treatments for AUD are hindered by low efficacy and poor adherence. He expressed that the new findings underscore AD04's potential to meet the critical needs of those suffering from AUD and ALD. The company views AD04 as a step towards precision treatment options that could significantly impact millions of people globally.
Adial Pharmaceuticals is advancing the development of treatments for addictions and related disorders. Its lead product, AD04, is a serotonin-3 receptor antagonist and was recently tested in the ONWARD pivotal Phase 3 clinical trial. The trial indicated promising results in reducing heavy drinking without overt safety or tolerability concerns.
The company believes that AD04 could also potentially address other addictive disorders such as Opioid Use Disorder, gambling, and obesity. However, the press release also contains forward-looking statements subject to various risks and uncertainties. These statements are not guarantees of future performance and should be considered with caution.
InvestingPro Insights
While Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) has reported promising clinical results for its investigational drug AD04, the company's financials tell a more nuanced story. According to real-time data from InvestingPro, Adial's market capitalization stands at a modest $4.58 million. The company's stock has experienced a significant downturn, with a one-year price total return of -84.4%, reflecting investor concerns and the inherent risks in pharmaceutical development.
An InvestingPro Tip highlights that Adial holds more cash than debt on its balance sheet, suggesting a degree of financial stability in the short term. However, it's also important to note that analysts do not anticipate the company will be profitable this year. This is consistent with the company's reported operating income, which was adjusted to a loss of $6.89 million over the last twelve months as of Q4 2023. Moreover, the stock has been characterized by high price volatility, which could indicate a higher risk profile for potential investors.
For those considering an investment in Adial Pharmaceuticals, it may be beneficial to explore the additional 10 InvestingPro Tips available, which provide deeper insights into the company's performance and outlook. Interested investors can take advantage of a special offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where these tips can be found.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.